Presenilins and γ-Secretase: Structure, Function, and Role in Alzheimer Disease

  1. Michael S. Wolfe4
  1. 1Center for Human Genetics, Leuven Institute for Neurodegenerative Diseases, KULeuven, 3000 Leuven, Belgium
  2. 2Department for Molecular and Developmental Genetics, VIB, 3000 Leuven, Belgium
  3. 3Department of Neuropathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan
  4. 4Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115
  1. Correspondence: mwolfe{at}rics.bwh.harvard.edu

Abstract

Presenilins were first discovered as sites of missense mutations responsible for early-onset Alzheimer disease (AD). The encoded multipass membrane proteins were subsequently found to be the catalytic components of γ-secretases, membrane-embedded aspartyl protease complexes responsible for generating the carboxyl terminus of the amyloid β-protein (Aβ) from the amyloid protein precursor (APP). The protease complex also cleaves a variety of other type I integral membrane proteins, most notably the Notch receptor, signaling from which is involved in many cell differentiation events. Although γ-secretase is a top target for developing disease-modifying AD therapeutics, interference with Notch signaling should be avoided. Compounds that alter Aβ production by γ-secretase without affecting Notch proteolysis and signaling have been identified and are currently at various stages in the drug development pipeline.

Also in this Collection

    | Table of Contents

    Richard Sever interviews Joan Brugge